Skip to main content
. Author manuscript; available in PMC: 2014 Aug 14.
Published in final edited form as: Sci Transl Med. 2012 Jan 25;4(118):118ra12. doi: 10.1126/scitranslmed.3003401

Fig.1. Humanized mouse reconstitution and treatment with teplizumab.

Fig.1

(A) FACS dot plot from peripheral blood of a representative humanized mouse prior to treatment showing the degree of human reconstitution. Staining for mouse CD45(mCD45), humanCD45 (hCD45), human CD8(hCD8), human CD4(hCD4), and human CD19(hCD19) after gating on total lymphocyte populations. (B) Humanized mouse reconstitution prior to treatment with teplizumab or control Ig (N=22). The percentage of hCD45+, CD4+, CD8+, and CD19+ human cells are shown for individual mice (the line designates median value). (C) CD4:CD8 ration in mice treated with tepilizumab or hIg showing decrease in the ratio following teplizumab treatment (* p < 0.05). (D) Coating of human CD3-T cell receptor (CD3-TCR) complex after a single injection of 5 μg of teplizumab (line histogram) or control Ig (gray histogram). Binding of OKT3 to T cells was significantly reduced in the teplizumab treated group (***p < 0.001, N= 11). The percent coating was 39 ± 8.39% (mean ± SEM).